Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $30.75 Average PT from Brokerages

Pacira BioSciences, Inc. (NASDAQ:PCRX) has earned a consensus rating of “Hold” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $30.75.

PCRX has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday. Truist Financial lowered their target price on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Barclays assumed coverage on shares of Pacira BioSciences in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $27.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a report on Friday, January 9th. Finally, Needham & Company LLC restated a “buy” rating and set a $30.00 target price on shares of Pacira BioSciences in a research note on Friday, January 9th.

Pacira BioSciences Trading Down 3.0%

Shares of NASDAQ:PCRX opened at $21.91 on Monday. The company has a market capitalization of $942.57 million, a PE ratio of 146.07 and a beta of 0.24. The company has a current ratio of 5.26, a quick ratio of 3.78 and a debt-to-equity ratio of 0.52. Pacira BioSciences has a 12-month low of $18.80 and a 12-month high of $27.64. The business’s fifty day simple moving average is $22.65 and its 200-day simple moving average is $23.85.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.57 earnings per share for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.16%. The company had revenue of $196.87 million for the quarter, compared to the consensus estimate of $201.93 million. During the same period in the previous year, the business earned $0.91 EPS. Pacira BioSciences’s revenue for the quarter was up 5.1% compared to the same quarter last year. As a group, equities research analysts predict that Pacira BioSciences will post 2.41 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Lauren Riker sold 4,000 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total value of $83,240.00. Following the completion of the transaction, the senior vice president directly owned 52,313 shares of the company’s stock, valued at $1,088,633.53. This trade represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Shawn Cross sold 9,104 shares of Pacira BioSciences stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $25.14, for a total transaction of $228,874.56. Following the completion of the sale, the chief financial officer owned 56,250 shares of the company’s stock, valued at $1,414,125. This trade represents a 13.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 30,416 shares of company stock valued at $744,315. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vident Advisory LLC grew its holdings in shares of Pacira BioSciences by 15.0% during the fourth quarter. Vident Advisory LLC now owns 23,571 shares of the company’s stock valued at $610,000 after buying an additional 3,075 shares during the last quarter. Empowered Funds LLC lifted its position in Pacira BioSciences by 1.9% during the 4th quarter. Empowered Funds LLC now owns 227,605 shares of the company’s stock worth $5,890,000 after acquiring an additional 4,167 shares during the period. XTX Topco Ltd purchased a new stake in Pacira BioSciences during the 4th quarter valued at about $2,146,000. Millennium Management LLC grew its stake in Pacira BioSciences by 73.3% during the 4th quarter. Millennium Management LLC now owns 122,606 shares of the company’s stock valued at $3,173,000 after purchasing an additional 51,848 shares during the last quarter. Finally, Inspire Investing LLC increased its holdings in shares of Pacira BioSciences by 3.2% in the fourth quarter. Inspire Investing LLC now owns 17,958 shares of the company’s stock valued at $465,000 after purchasing an additional 556 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences News Roundup

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Record EXPAREL sales — Pacira said EXPAREL delivered its strongest fourth-quarter performance in three years, driven by 7% volume growth, signaling solid demand for its core product. GlobeNewswire Release
• Neutral Sentiment: Company provided FY-2026 revenue guidance of $745.0 million to $770.0 million (versus consensus ~$766.9M); range implies growth but sits slightly below the consensus midpoint, leaving interpretation mixed for investors. Guidance Detail
• Neutral Sentiment: Full earnings materials and call resources are available (earnings press release, slide deck and call transcripts), useful for investors wanting management commentary on margin drivers and expense cadence. Slide Deck Earnings Call Transcript
• Negative Sentiment: Earnings and revenue missed estimates — Pacira reported Q4 EPS of $0.57 vs. consensus $0.85 and revenue of $196.9M vs. $201.9M expected; the EPS shortfall and top-line miss are primary drivers of the negative price reaction. MarketBeat Earnings Summary
• Negative Sentiment: Rising expenses pressured margins — management flagged higher operating costs that reduced net income and contributed to the EPS miss, raising near-term profitability concerns. Zacks Coverage

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.